KeyBanc raises ResMed stock price target on FY27 outlook confidence

ResMed shares received a boost as KeyBanc raised its price target to $267 from $255 (Overweight) after meeting management on Aug. 31, 2026, citing improved comfort with the FY2027 outlook and room for sentiment recovery. On the latest results, ResMed delivered non-GAAP EPS of $2.95 vs. $2.89 expected (+16% YoY) but revenue of $1.46B slightly missed the $1.47B estimate. KeyBanc also highlighted balance-sheet/free-cash-flow support for portfolio actions and ongoing share repurchases, reinforcing a modestly positive setup despite mixed earnings reaction.

Analysis

This is a multiple-expansion setup more than a near-term earnings revision story. The important mechanism is that buybacks plus high recurring cash flow can support a floor even if top-line growth stays only mid-single digits, so incremental confidence on outer-year visibility matters more than the latest quarter miss. In other words, the stock is sensitive to the market’s willingness to pay up for durability; if management keeps reinforcing FY27/FY30 targets, the valuation debate can shift from “is growth decelerating?” to “how much is the platform worth through the cycle?”

The key loser in the ecosystem is not a single named rival but any legacy sleep-apnea supplier relying on price competition or channel share to offset category headwinds. If GLP-1 adoption is truly slowing new patient flow, the second-order effect is that the market will discount not just unit growth but installed-base replacement economics; that would pressure the entire sleep-device group’s multiples, not just this name. Conversely, if obesity-drug penetration increases screening and diagnosis rates, the consensus bearish GLP-1 narrative may be overstated: more treated obesity could enlarge the addressable pool of diagnosed sleep apnea patients over 6-18 months.

The immediate catalyst window is 1-3 months: next prints, channel commentary, and any evidence that share repurchases are offsetting moderation in organic growth. The main falsifier is not valuation—it is either a downward revision to outer-year visibility or a sign that U.S. competitive intensity is forcing pricing/volume tradeoffs. If the stock fails to hold the low-230s after the next update, the market is likely saying the re-rating case is capped until there is harder evidence of accelerating growth, regardless of analyst target moves.

Key Decisions for Investors

• Long RMD on dips into the $230-235 area with a 3-6 month target toward $267-275; stop if management trims FY27 visibility or if the stock loses the low-$230s on heavy volume.
• Pair trade: long RMD / short XLV for 1-3 months to isolate idiosyncratic rerating versus broad medtech beta; thesis fails if GLP-1 commentary or competitive checks deteriorate materially.
• If already long, consider selling out-of-the-money calls against the position into strength near the updated target to monetize the valuation ceiling while preserving core upside from buybacks.
• Watch for the next quarterly call as the decisive catalyst; if gross margin or share-repurchase pace weakens, reduce exposure because the investment case depends on capital return supporting the multiple.